Published in Antimicrob Agents Chemother on July 01, 2003
Enhanced cancer cell growth inhibition by dipeptide prodrugs of floxuridine: increased transporter affinity and metabolic stability. Mol Pharm (2008) 0.93
Impact of peptide transporter 1 on the intestinal absorption and pharmacokinetics of valacyclovir after oral dose escalation in wild-type and PepT1 knockout mice. Drug Metab Dispos (2013) 0.89
Time profile of viral DNA in aqueous humor samples of patients treated for varicella-zoster virus acute retinal necrosis by use of quantitative real-time PCR. J Clin Microbiol (2013) 0.80
The development of orally administrable gemcitabine prodrugs with D-enantiomer amino acids: enhanced membrane permeability and enzymatic stability. Eur J Pharm Biopharm (2013) 0.78
[Acute retinal necrosis from the virologist's perspective]. Ophthalmologe (2009) 0.77
[Acute retinal necrosis: Clinical features and therapy options]. Ophthalmologe (2009) 0.75
The dipeptide monoester prodrugs of floxuridine and gemcitabine-feasibility of orally administrable nucleoside analogs. Pharmaceuticals (Basel) (2014) 0.75
In Vitro and Clinical Evaluations of the Drug-Drug Interaction Potential of a Metabotropic Glutamate 2/3 Receptor Agonist Prodrug at PEPT1. Drug Metab Dispos (2016) 0.75
5'-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm Res (1998) 1.66
Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics (2002) 1.57
Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2. Biochem Biophys Res Commun (1998) 1.43
Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir. Biochem Biophys Res Commun (1998) 1.33
Uptake of the cephalosporin, cephalexin, by a dipeptide transport carrier in the human intestinal cell line, Caco-2. Biochim Biophys Acta (1990) 1.29
Interactions of a nonpeptidic drug, valacyclovir, with the human intestinal peptide transporter (hPEPT1) expressed in a mammalian cell line. J Pharmacol Exp Ther (1999) 1.12
Cellular uptake mechanism of amino acid ester prodrugs in Caco-2/hPEPT1 cells overexpressing a human peptide transporter. Pharm Res (1998) 1.07
Transport of L-valine-acyclovir via the oligopeptide transporter in the human intestinal cell line, Caco-2. J Pharmacol Exp Ther (1998) 1.06
Rat multispecific organic anion transporter 1 (rOAT1) transports zidovudine, acyclovir, and other antiviral nucleoside analogs. J Pharmacol Exp Ther (2000) 1.06
Membrane transporters. Eur J Pharm Sci (2000) 1.05
Correlation between epithelial cell permeability of cephalexin and expression of intestinal oligopeptide transporter. J Pharmacol Exp Ther (2001) 0.93
Functional expression of transporter for beta-lactam antibiotics and dipeptides in Xenopus laevis oocytes injected with messenger RNA from human, rat and rabbit small intestines. J Pharmacol Exp Ther (1995) 0.83
Strategies and methods for research on sex differences in brain and behavior. Endocrinology (2004) 5.02
A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med (2009) 3.86
ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res (2005) 3.52
MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther (2008) 3.06
3-Iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone. Nat Med (2004) 2.96
Training the next generation of research mentors: the University of California, San Francisco, Clinical & Translational Science Institute Mentor Development Program. Clin Transl Sci (2009) 2.60
MicroRNA expression profiles for the NCI-60 cancer cell panel. Mol Cancer Ther (2007) 2.53
Pharmacogenomic testing: relevance in medical practice: why drugs work in some patients but not in others. Cleve Clin J Med (2011) 2.43
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin Pharmacol Ther (2013) 2.39
Impact of emerging technologies on medication errors and adverse drug events. Am J Health Syst Pharm (2003) 2.14
Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res (2004) 2.10
Desired vancomycin trough serum concentration for treating invasive methicillin-resistant Staphylococcal infections. Pediatr Infect Dis J (2013) 1.91
Innate immune gene polymorphisms in tuberculosis. Infect Immun (2012) 1.89
The human zinc transporter SLC39A8 (Zip8) is critical in zinc-mediated cytoprotection in lung epithelia. Am J Physiol Lung Cell Mol Physiol (2008) 1.45
Sensitive analysis of anti-HIV drugs, efavirenz, lopinavir and ritonavir, in human hair by liquid chromatography coupled with tandem mass spectrometry. Rapid Commun Mass Spectrom (2008) 1.44
Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate. Pediatr Infect Dis J (2009) 1.43
KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST). Pharmacogenet Genomics (2007) 1.40
Functional variants of the dopamine receptor D2 gene modulate prefronto-striatal phenotypes in schizophrenia. Brain (2008) 1.37
Cytochrome P450 eicosanoids are activators of peroxisome proliferator-activated receptor alpha. Drug Metab Dispos (2007) 1.35
In-vitro activity of miltefosine and voriconazole on clinical isolates of free-living amebas: Balamuthia mandrillaris, Acanthamoeba spp., and Naegleria fowleri. J Eukaryot Microbiol (2006) 1.35
Basal signaling activity of mu opioid receptor in mouse brain: role in narcotic dependence. J Pharmacol Exp Ther (2003) 1.32
Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia. Cancer Chemother Pharmacol (2006) 1.31
Risk factors for community-acquired ciprofloxacin-resistant Escherichia coli urinary tract infection. Ann Pharmacother (2004) 1.30
Intronic polymorphisms affecting alternative splicing of human dopamine D2 receptor are associated with cocaine abuse. Neuropsychopharmacology (2010) 1.29
Bcl9/Bcl9l are critical for Wnt-mediated regulation of stem cell traits in colon epithelium and adenocarcinomas. Cancer Res (2010) 1.28
Polymorphisms affecting gene regulation and mRNA processing: broad implications for pharmacogenetics. Pharmacol Ther (2004) 1.26
Genetically determined measures of striatal D2 signaling predict prefrontal activity during working memory performance. PLoS One (2010) 1.24
Nicotinic α5 receptor subunit mRNA expression is associated with distant 5' upstream polymorphisms. Eur J Hum Genet (2010) 1.23
Cholesteryl Ester Transfer Protein (CETP) polymorphisms affect mRNA splicing, HDL levels, and sex-dependent cardiovascular risk. PLoS One (2012) 1.21
Microanalysis of the antiretroviral nevirapine in human hair from HIV-infected patients by liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem (2011) 1.18
Genetically determined interaction between the dopamine transporter and the D2 receptor on prefronto-striatal activity and volume in humans. J Neurosci (2009) 1.18
Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist pretreatment. J Pharmacol Exp Ther (2007) 1.16
Common CYP2D6 polymorphisms affecting alternative splicing and transcription: long-range haplotypes with two regulatory variants modulate CYP2D6 activity. Hum Mol Genet (2013) 1.16
Dose-response effect of tetracyclines on cerebral matrix metalloproteinase-9 after vascular endothelial growth factor hyperstimulation. J Cereb Blood Flow Metab (2006) 1.15
Protein therapeutics: new applications for pharmacogenetics. Nat Rev Drug Discov (2006) 1.15
Dopamine transporter gene variant affecting expression in human brain is associated with bipolar disorder. Neuropsychopharmacology (2011) 1.13
Functional variation of the dopamine D2 receptor gene is associated with emotional control as well as brain activity and connectivity during emotion processing in humans. J Neurosci (2009) 1.11
The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med (2010) 1.10
Impact of a piperacillin-tazobactam shortage on antimicrobial prescribing and the rate of vancomycin-resistant enterococci and Clostridium difficile infections. Pharmacotherapy (2006) 1.10
Impact of a hospitalwide increase in empiric pediatric vancomycin dosing on initial trough concentrations. Pharmacotherapy (2011) 1.09
Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone: lack of dose proportionality. Clin Pharmacokinet (2004) 1.09
Allele-specific tumor spectrum in pten knockin mice. Proc Natl Acad Sci U S A (2010) 1.08
Systematic review of medication safety assessment methods. Am J Health Syst Pharm (2011) 1.08
Feasibility of minocycline and doxycycline use as potential vasculostatic therapy for brain vascular malformations: pilot study of adverse events and tolerance. Cerebrovasc Dis (2008) 1.07
Program in pharmacogenomics at the Ohio State University Medical Center. Pharmacogenomics (2012) 1.07
Response to paper by Kelly et al "The opioid receptor pharmacology of GSK1521498 compared to other ligands with different effects on compulsive reward-related behaviors" published in Psychopharmacology 232, 305-314, 2014. Psychopharmacology (Berl) (2015) 1.05
A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res (2009) 1.04
HIV-associated disruption of mucosal epithelium facilitates paracellular penetration by human papillomavirus. Virology (2013) 1.04
Pharmacokinetics and tolerability of oseltamivir combined with probenecid. Antimicrob Agents Chemother (2008) 1.00
Impact of HIV-specialized pharmacies on adherence and persistence with antiretroviral therapy. AIDS Patient Care STDS (2012) 0.99
Whole transcriptome RNA-Seq allelic expression in human brain. BMC Genomics (2013) 0.99
Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition. PLoS One (2010) 0.99
Short term impact of guidelines on vancomycin dosing and therapeutic drug monitoring. Int J Clin Pharm (2012) 0.98
Antimicrobial stewardship programs: interventions and associated outcomes. Expert Rev Anti Infect Ther (2008) 0.98
Daptomycin treatment failure for vancomycin-resistant Enterococcus faecium infective endocarditis: impact of protein binding? Ann Pharmacother (2008) 0.98
Functional analysis of polymorphisms in the organic anion transporter, SLC22A6 (OAT1). Pharmacogenet Genomics (2005) 0.98
Pharmacokinetics of quinacrine in the treatment of prion disease. BMC Infect Dis (2004) 0.98
Effect of sex and AIDS status on the plasma and intrapulmonary pharmacokinetics of rifampicin. Clin Pharmacokinet (2004) 0.97
Human N-acetyltransferase 1 *10 and *11 alleles increase protein expression through distinct mechanisms and associate with sulfamethoxazole-induced hypersensitivity. Pharmacogenet Genomics (2011) 0.97
Pharmacokinetics of valaciclovir. J Antimicrob Chemother (2004) 0.95
Boxed warning inconsistencies between drug information resources and the prescribing information. Am J Health Syst Pharm (2011) 0.95
CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response. Circ Cardiovasc Genet (2009) 0.94
Financial and psychological risk attitudes associated with two single nucleotide polymorphisms in the nicotine receptor (CHRNA4) gene. PLoS One (2009) 0.93
Voriconazole-associated cutaneous malignancy: a literature review on photocarcinogenesis in organ transplant recipients. Clin Infect Dis (2013) 0.92
Diagnosis and treatment of extended-spectrum and AmpC beta-lactamase-producing organisms. Ann Pharmacother (2007) 0.92
Defining new criteria for selection of cell-based intestinal models using publicly available databases. BMC Genomics (2012) 0.91
Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trial. BMC Infect Dis (2014) 0.91
Quinacrine is mainly metabolized to mono-desethyl quinacrine by CYP3A4/5 and its brain accumulation is limited by P-glycoprotein. Drug Metab Dispos (2006) 0.91
Improved antiretroviral refill adherence in HIV-focused community pharmacies. J Am Pharm Assoc (2003) (2012) 0.90
mRNA transcript diversity creates new opportunities for pharmacological intervention. Mol Pharmacol (2012) 0.89
FOXQ1, a novel target of the Wnt pathway and a new marker for activation of Wnt signaling in solid tumors. PLoS One (2013) 0.89
Gentamicin pharmacokinetics and dosing in neonates with hypoxic ischemic encephalopathy receiving hypothermia. Pharmacotherapy (2013) 0.89
Possible neuropsychiatric reaction to high-dose oseltamivir during acute 2009 H1N1 influenza A infection. Clin Infect Dis (2010) 0.89
Chemoinformatics analysis identifies cytotoxic compounds susceptible to chemoresistance mediated by glutathione and cystine/glutamate transport system xc-. J Med Chem (2007) 0.88
Antimicrobial drug prescribing for pneumonia in ambulatory care. Emerg Infect Dis (2005) 0.88
Genotyping panel for assessing response to cancer chemotherapy. BMC Med Genomics (2008) 0.88
Assessment of FANCD2 nuclear foci formation in paraffin-embedded tumors: a potential patient-enrichment strategy for treatment with DNA interstrand crosslinking agents. Transl Res (2012) 0.86
5-Aza-2'-deoxycytidine and depsipeptide synergistically induce expression of BIK (BCL2-interacting killer). Biochem Biophys Res Commun (2006) 0.86
Multiple regulatory variants modulate expression of 5-hydroxytryptamine 2A receptors in human cortex. Biol Psychiatry (2012) 0.86
Raccoon Roundworm Infection Associated with Central Nervous System Disease and Ocular Disease - Six States, 2013-2015. MMWR Morb Mortal Wkly Rep (2016) 0.86
Patterns of antibacterial use and impact of age, race/ethnicity, and geographic region on antibacterial use in an outpatient medicaid cohort. Pharmacotherapy (2014) 0.85
Regional variations in ABC transporter expression along the mouse intestinal tract. Physiol Genomics (2004) 0.85
Comparative safety of antipsychotics in the WHO pharmacovigilance database: the haloperidol case. Int J Clin Pharm (2011) 0.85
Compliance in two medical centers with criteria for use of caspofungin and lipid-based amphotericin B. Am J Health Syst Pharm (2004) 0.85
Risk factors and risk adjustment for surgical site infections in pediatric cardiothoracic surgery patients. Am J Infect Control (2010) 0.84
Genomic architecture of pharmacological efficacy and adverse events. Pharmacogenomics (2014) 0.83
How the gut links innate and adaptive immunity. Ann N Y Acad Sci (2004) 0.82
A pharmacoproteomics study of the cancer cell line EKVX using capillary-LC/MS/MS. Mol Pharm (2006) 0.81
Cannabinoid receptor trafficking in peripheral cells is dynamically regulated by a binary biochemical switch. Biochem Pharmacol (2012) 0.81
Transporter and ion channel gene expression after Caco-2 cell differentiation using 2 different microarray technologies. AAPS J (2004) 0.81
Antifungal prophylaxis in chemotherapy-associated neutropenia: a retrospective, observational study. BMC Infect Dis (2007) 0.81
CYP3A4/5 combined genotype analysis for predicting statin dose requirement for optimal lipid control. Drug Metabol Drug Interact (2013) 0.81
Regulation of cholesteryl ester transfer protein expression by upstream polymorphisms: reduced expression associated with rs247616. Pharmacogenet Genomics (2015) 0.80
Antimicrobial therapy of gram-negative bacteremia at two university-affiliated medical centers. Am J Med (2002) 0.80
6β-naltrexol, a peripherally selective opioid antagonist that inhibits morphine-induced slowing of gastrointestinal transit: an exploratory study. Pain Med (2011) 0.80
Solute carriers (SLCs) in cancer. Mol Aspects Med (2013) 0.79
Co-administration of a commonly used Zimbabwean herbal treatment (African potato) does not alter the pharmacokinetics of lopinavir/ritonavir. Int J Infect Dis (2013) 0.79